SPRINTR – Swedish PRostate cancer Initiative for Novel Treatment Regimens Biomarker driven precision medicine in non-metastatic high-risk prostate cancer

Yearly, 2100 Swedish men die from prostate cancer (PC).

About 50 % of these were first diagnosed with non-metastatic high-risk PC (HR-PC) and offered curative treatment that failed.

With improved personalized therapies for HR-PC, progression to metastatic, lethal disease could be limited, and lives saved. We aim to establish an infrastructure for observational and precision medicine trials (www.sprintr.se). This planning phase aims to facilitate the development of a national platform for clinical research in prostate cancer.

SPRINTR-RealAll men biopsied for suspected PC will be invited to SPRINTR-Real, a prospective observational study.

Men consent to 1) comprehensive profiling of the diagnostic prostate biopsy (molecular, imaging, and digital pathology), 2) follow-up through the clinical tool IPÖ (INCA.se) and registers, 3) be selectively invited to suitable studies/trials based on collected data.

Implementing SPRINTR-Real in the diagnostic workflow will greatly increase the potential for efficient recruitment to any trial in Sweden.

SPRINTR-Trial  Patients with HR-PC will be invited to SPRINTR-Trial and the full profiling of the biopsy will generate biomarker data to be used in classifier algorithms established in parallel (sprintr.se) for weighted randomization. SPRINTR-Trial is a biomarker-driven multi-arm adaptive randomized clinical trial platform.

Based on accumulated evidence during the study, arms and algorithms may be modified, and experimental arms will be added.